Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPR119-LW1
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Jinan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GPR119-LW1 (specifically evaluated as the radiolabeled PET tracer [18F]GPR119-LW1) is a novel positron emission tomography (PET) imaging agent targeting G protein-coupled receptor 119 (GPR119). GPR119 is predominantly expressed in pancreatic β-cells and plays a key role in glucose-dependent insulin secretion, making it a valuable biomarker for pancreatic dysfunction in diabetes. Developed by researchers at the First Affiliated Hospital of Jinan University and Emory University, GPR119-LW1 is designed for noninvasive visualization and quantification of pancreatic GPR119 expression. Preclinical studies in healthy and diabetic mouse models (such as db/db and diet-induced obesity mice) demonstrated consistent pancreatic tracer uptake that decreases with progressive pancreatic dysfunction. Preliminary clinical translation in patients with diabetes has supported the feasibility of using [18F]GPR119-LW1 to image pancreatic GPR119 expression in humans, showing a decreasing trend in tracer uptake with increasing disease severity.
- Other names
- 18F-GPR119-LW1[18F]GPR119-LW1[¹⁸F]GPR119-LW1
02
Targets
GPR119 (Glucose-dependent insulinotropic receptor)
Beyond the preview
Go deeper on GPR119-LW1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPR119-LW1.